In the past week, ABOS stock has gone up by 11.57%, with a monthly gain of 46.15% and a quarterly surge of 2.54%. The volatility ratio for the week is 8.57%, and the volatility levels for the last 30 days are 7.95% for Acumen Pharmaceuticals Inc The simple moving average for the past 20 days is 28.71% for ABOS’s stock, with a -0.59% simple moving average for the past 200 days.
Is It Worth Investing in Acumen Pharmaceuticals Inc (NASDAQ: ABOS) Right Now?
Company’s 36-month beta value is 0.10.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ABOS is 44.37M, and currently, short sellers hold a 2.23% ratio of that floaft. The average trading volume of ABOS on July 23, 2024 was 408.03K shares.
ABOS) stock’s latest price update
Acumen Pharmaceuticals Inc (NASDAQ: ABOS)’s stock price has soared by 12.54 in relation to previous closing price of 2.87. Nevertheless, the company has seen a gain of 11.57% in its stock price over the last five trading days. seekingalpha.com reported 2024-05-14 that Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Alex Braun – Vice President & Head of Investor Relations Daniel O’Connell – Chief Executive Officer Matt Zuga – Chief Financial Officer & Chief Business Officer Eric Siemers – Chief Medical Officer Conference Call Participants Tom Shrader – BTIG Samantha Schaeffer – Cantor Fitzgerald Jason Zemansky – Bank of America Operator Good day and thank you for standing by. Welcome to Acumen Pharmaceuticals First Quarter 2024 Conference Call and Webcast.
Analysts’ Opinion of ABOS
Many brokerage firms have already submitted their reports for ABOS stocks, with Deutsche Bank repeating the rating for ABOS by listing it as a “Buy.” The predicted price for ABOS in the upcoming period, according to Deutsche Bank is $8 based on the research report published on December 12, 2023 of the previous year 2023.
BofA Securities, on the other hand, stated in their research note that they expect to see ABOS reach a price target of $14, previously predicting the price at $9. The rating they have provided for ABOS stocks is “Buy” according to the report published on July 20th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to ABOS, setting the target price at $13 in the report published on May 18th of the previous year.
ABOS Trading at 13.35% from the 50-Day Moving Average
After a stumble in the market that brought ABOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.27% of loss for the given period.
Volatility was left at 7.95%, however, over the last 30 days, the volatility rate increased by 8.57%, as shares surge +39.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.00% lower at present.
During the last 5 trading sessions, ABOS rose by +11.57%, which changed the moving average for the period of 200-days by -23.10% in comparison to the 20-day moving average, which settled at $2.56. In addition, Acumen Pharmaceuticals Inc saw -15.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABOS starting from OConnell Daniel Joseph, who sale 15,200 shares at the price of $3.47 back on Jan 19 ’24. After this action, OConnell Daniel Joseph now owns 502,485 shares of Acumen Pharmaceuticals Inc, valued at $52,753 using the latest closing price.
Meisner Derek M, the Chief Legal Officer & Corp Sec of Acumen Pharmaceuticals Inc, sale 8,933 shares at $3.48 during a trade that took place back on Jan 19 ’24, which means that Meisner Derek M is holding 108,867 shares at $31,048 based on the most recent closing price.
Stock Fundamentals for ABOS
Current profitability levels for the company are sitting at:
- -226.82 for the present operating margin
- 0.39 for the gross margin
The net margin for Acumen Pharmaceuticals Inc stands at -192.89. The total capital return value is set at -0.22. Equity return is now at value -25.36, with -22.89 for asset returns.
Based on Acumen Pharmaceuticals Inc (ABOS), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -1.67. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is 156.99.
Currently, EBITDA for the company is -60.95 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 612.79. The receivables turnover for the company is 1.53for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 30.20.
Conclusion
In a nutshell, Acumen Pharmaceuticals Inc (ABOS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
